- Trial phase
- Approved (FDA since 2018)
- Time to market
- Already on the market (approved in the US since 2018, in China since 2023).
- Why 3/10
- XERAVA is an approved, marketed drug with no pending regulatory decision, PDUFA date, or scheduled pivotal readout in the next ~12 months. It contributes a small fraction (about 3%) of Innoviva's total revenue, behind the company's larger GSK royalty stream and its other IST products GIAPREZA and XACDURO. Per the impact scoring rubric, an approved drug with no imminent binary catalyst defaults to 3-5, and the drug's modest revenue share places it at the lower end of that range.
XERAVA has no scheduled binary catalyst to watch. The next relevant event for Innoviva overall is the Q3 2026 earnings call on November 11, 2026, which will report aggregate IST product sales. Investors interested in XERAVA-specific signals should track pediatric trial results (NCT06794541) and any updates to IDSA/SIS treatment guidelines, but neither provides a hard, dated binary for the stock.
Price Chart
Executive Summary
XERAVA (eravacycline) is an FDA-approved intravenous antibiotic for complicated intra-abdominal infections (cIAI), originally developed by Tetraphase Pharmaceuticals and now marketed in the US by Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA). Despite its clinical utility against multi-drug resistant pathogens, XERAVA is a niche product with modest sales ($3.4M in Q3 2026 U.S. net product sales) and faces heavy competition from generic carbapenems and other branded antibiotics. For Innoviva, XERAVA is the smallest of three commercial products behind GIAPREZA and XACDURO, and the company's primary value driver remains its GSK royalty portfolio. No upcoming regulatory catalysts are expected for this drug.
How It Works
XERAVA is a synthetic fluorocycline antibiotic (part of the tetracycline family) given intravenously in hospitals. It kills bacteria by blocking their ability to produce the proteins they need to survive. Its chemical structure is modified to evade many common antibiotic-resistance mechanisms that have rendered older tetracyclines less effective.
Trial Status
XERAVA was approved by the FDA in August 2018 based on two Phase 3 trials (IGNITE 1 and IGNITE 4) that showed it was as effective as carbapenem antibiotics for complicated intra-abdominal infections (cIAI). A Phase 2 pediatric trial in patients aged 8-17 is ongoing (NCT06794541). An oral formulation was discontinued after a Phase 3 trial in urinary tract infections failed to meet its goals. Real-world evidence continues to be published, including subpopulation analyses and studies in carbapenem-resistant infections.
The Two-Sided Case
Upcoming Catalysts
- No hard, dated regulatory binary catalyst (PDUFA, AdComm, or pivotal readout) is scheduled for XERAVA in the next ~12 months. A Phase 2 pediatric safety trial is ongoing but has not disclosed a topline readout date. Innoviva presents IDWeek data in late 2026, but these are scientific presentations, not registration catalysts.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Innoviva, Inc. 8-K INVA ·Originating report